JP2009540842A - Ｃｍｖ感染に関連する疾患の治療のための免疫毒素 - Google Patents

Ｃｍｖ感染に関連する疾患の治療のための免疫毒素 Download PDF

Info

Publication number
JP2009540842A
JP2009540842A JP2009516907A JP2009516907A JP2009540842A JP 2009540842 A JP2009540842 A JP 2009540842A JP 2009516907 A JP2009516907 A JP 2009516907A JP 2009516907 A JP2009516907 A JP 2009516907A JP 2009540842 A JP2009540842 A JP 2009540842A
Authority
JP
Japan
Prior art keywords
seq
immunotoxin
ligand
mutated
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009516907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540842A5 (enExample
Inventor
クレダル，トーマス，ニットシュケ
マリー ローゼンキルド ロエド，メッテ
Original Assignee
イナゲン エイピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イナゲン エイピーエス filed Critical イナゲン エイピーエス
Publication of JP2009540842A publication Critical patent/JP2009540842A/ja
Publication of JP2009540842A5 publication Critical patent/JP2009540842A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009516907A 2006-07-03 2007-07-03 Ｃｍｖ感染に関連する疾患の治療のための免疫毒素 Pending JP2009540842A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600900 2006-07-03
PCT/DK2007/050082 WO2008003327A2 (en) 2006-07-03 2007-07-03 Immunotoxins for the treatment of diseases related to cmv infection

Publications (2)

Publication Number Publication Date
JP2009540842A true JP2009540842A (ja) 2009-11-26
JP2009540842A5 JP2009540842A5 (enExample) 2010-08-19

Family

ID=38739380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009516907A Pending JP2009540842A (ja) 2006-07-03 2007-07-03 Ｃｍｖ感染に関連する疾患の治療のための免疫毒素

Country Status (5)

Country Link
US (1) US8592554B2 (enExample)
EP (1) EP2038302B1 (enExample)
JP (1) JP2009540842A (enExample)
CA (1) CA2656992A1 (enExample)
WO (1) WO2008003327A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022540877A (ja) * 2019-07-12 2022-09-20 ケブンハウン ユニヴェルスィテイト Ｃｍｖ感染に関連する疾患の治療のための融合毒素タンパク質

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US20220324947A1 (en) * 2019-08-05 2022-10-13 Stichting Vu Identification and Elimination of HCMV-Infected Cells
MX2022002628A (es) * 2019-09-03 2022-03-25 Synklino Aps Proteinas de fusion y usos de las mismas.
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521019A (ja) * 1998-07-22 2002-07-16 オスプレイ・ファルマシューティカルズ・リミテッド 二次的組織損傷ならびにその他の炎症症状および疾患を治療する方法および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CA2240409C (en) * 1996-01-24 2011-03-22 Schering Corporation Mammalian cx3c chemokine genes
CA2301846A1 (en) * 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
CA2341361A1 (en) * 1998-08-31 2000-03-09 Oregon Health Sciences University Prevention of cell migration initiation with cmv us28 receptor antagonists
EP1272512A4 (en) 2000-03-23 2003-05-07 Phylomed Corp IMMUNOKIN COMPOSITION AND METHOD
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
US20050136033A9 (en) 2002-08-13 2005-06-23 Matthias Mack Method of treating allergen induced airway disease
CN1768862A (zh) * 2004-10-26 2006-05-10 北京诺思兰德生物技术有限责任公司 一类能与表达GnRH受体的癌细胞特异结合且用锝－99m标记的蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521019A (ja) * 1998-07-22 2002-07-16 オスプレイ・ファルマシューティカルズ・リミテッド 二次的組織損傷ならびにその他の炎症症状および疾患を治療する方法および組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022540877A (ja) * 2019-07-12 2022-09-20 ケブンハウン ユニヴェルスィテイト Ｃｍｖ感染に関連する疾患の治療のための融合毒素タンパク質

Also Published As

Publication number Publication date
CA2656992A1 (en) 2008-01-10
WO2008003327A3 (en) 2008-02-21
US8592554B2 (en) 2013-11-26
EP2038302A2 (en) 2009-03-25
US20100048470A1 (en) 2010-02-25
EP2038302B1 (en) 2012-10-24
WO2008003327A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
KR102165464B1 (ko) Cd22에 대해 특이적인 항체 및 이들의 사용 방법
US5270199A (en) Human mannose-binding protein
CN107427574B (zh) Cxcr4结合分子
JP2009540842A (ja) Ｃｍｖ感染に関連する疾患の治療のための免疫毒素
JP2002527100A (ja) インターフェロン−β融合タンパク質および使用
TWI794897B (zh) Ｇｌｐ-２衍生物之長效接合物
KR101695056B1 (ko) 카드헤린-11의 ec1 도메인을 표적으로 하는 인간화 항체 및 관련 조성물 및 방법
WO2021213478A1 (zh) 抗人b7-h3的单克隆抗体及其应用
JP2023528797A (ja) ガレクチン－３を遮断することにより炎症性疾患を処置する方法
JP6735822B2 (ja) Ｉｌ２２免疫コンジュゲート
WO2020119728A1 (zh) 抗人白细胞介素5(il-5)单克隆抗体及其应用
KR20230110297A (ko) 소 항체 변이체
WO2021237516A1 (zh) Sars-cov-2抗体及其应用
TWI238191B (en) IL-17 like molecules and uses thereof
TW202237634A (zh) 用於治療ｃｏｖｉｄ－１９之ｄｓｇ２組成物和方法
JP2008535909A (ja) Ｍｃｐ−１／ｃｃｒ２関連疾患を治療するための分子およびその使用方法
KR20220032610A (ko) Cmv 감염과 관련된 질병 치료를 위한 융합 독소 단백질
KR20240139054A (ko) 가교 항체
WO2024008126A1 (en) Il2 muteins and uses thereof
WO2025179282A1 (en) Antibodies targeting epstein-barr virus proteins and methods of use
JP2025536308A (ja) 新規なＮａＰｉ２ｂ抗体を有する新規な抗体－薬物コンジュゲート、治療的方法、ならびにそれらの使用
CN120202023A (zh) 涉及整合素α3β1的组合物和方法
KR20180095013A (ko) 사멸 수용체 작용제로 전신성 경화증 완화
HK1227417B (zh) 能够中和狂犬病毒的结合分子
NZ715807A (en) Polypeptide constructs and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140114